Announcements Trials
Browse Landscape

Status

Available 2Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 214Observational 45Expanded_access 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 34Multiple Myeloma 32Recurrence 29Prostatic Neoplasms 28Melanoma 21Leukemia, Myeloid, Acute 21Breast Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Glioblastoma 15Pancreatic Neoplasms 14Sarcoma 13Neuroblastoma 13Lymphoma 13Glioma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 10Ovarian Neoplasms 9Lung Neoplasms 9Colorectal Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Lymphoma, Large B-Cell, Diffuse 8Lambert-Eaton Myasthenic Syndrome 8Pheochromocytoma 7Neuroendocrine Tumors 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Gastrointestinal Stromal Tumors 7Carcinoma, Renal Cell 7

Interventions

dodecyl maltoside 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Non-Muscle Invasive Bladder Neoplasms × Clear all
NCT06810141 2026-05-14

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

ImmunityBio, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT06877676 2026-04-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡